AzurRx’s Phase II OPTION study of MS1819-SD achieves enrollment target
Category: #healthcare  By Mateen Dalal  Date: 2019-05-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

AzurRx’s Phase II OPTION study of MS1819-SD achieves enrollment target

It has reached the enrollment target of 30-35 patients that was determined when the OPTION study was started in December 2018

AzurRx BioPharma has recently confirmed that it has achieved its enrollment target of 30-35 patients in the ongoing Phase II OPTION study of MS1819-SD in cystic fibrosis (CF) patients, for exocrine pancreatic insufficiency. The company reportedly specializes in the development of recombinant, non-systemic therapies for gastrointestinal diseases.

Seemingly, AzurRx BioPharma has completed its screening activities for enrollment of the study, which is rolling out across investigative sites in Poland and North America. Top-line results for the OPTION study are anticipated in Summer 2019.

Sources familiar with the matter informed that the Phase II multi-center OPTION clinical trial is formally designed to examine the efficacy, tolerability, and safety of MS1819-SD by comparing it head-to-head against the present porcine pancreatic enzyme replacement therapy with standard of care for exocrine pancreatic insufficiency in patients with CF.  

According to Chief Executive Officer of AzurRx, Thijs Spoor, the company has reached the enrollment target of 30-35 patients that was determined when the OPTION study was started in December 2018.

Apparently, the OPTION study is a Phase II, multicenter, open-label, and 2x2 crossover study evaluating the efficacy and safety of MS1819-SD against porcine PERT when given the same dosage during the period of pre-study. Both crossover periods will be completed by around 30 evaluable CF patients. The primary efficacy endpoint would involve comparing the coefficient of fat absorption (CFAs) following both the crossover stages.

For the uninitiated, AzurRx BioPharma is involved in the R&D of non-systemic biologics for treating patients experiencing gastrointestinal disorders. MS1819-SD recombinant lipase is the lead development program of the company. Along with this, an additional early stage research is being performed for preventing hospital-acquired infections. The headquarter of the company is in Brooklyn, NY and it has scientific operations located in Langlade, France. 

Source Credit: https://www.saurenergy.com/solar-energy-news/microsoft-signs-purchase-agreement-for-90-mw-wind-power-with-eneco

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

TikTok owner ByteDance in talks to enter subscription music business
TikTok owner ByteDance in talks to enter subscription music business
By Mateen Dalal

Beijing ByteDance Technology Co Ltd, owner of popular short-video app TikTok has recently announced ...

Kiniksa Pharma releases final phase 2 clinical data for rilonacept
Kiniksa Pharma releases final phase 2 clinical data for rilonacept
By Mateen Dalal

Data renders evidence of clinically improved outcome in recurrent pericarditis   Results we...

U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
By Mateen Dalal

Shionogi & Co., Ltd., a Japan-based pharmaceutical company recently announced approval of drug c...